01741nam 2200553 a 450 991078186510332120200520144314.01-61324-967-5(CKB)2550000000060301(EBL)3019696(SSID)ssj0000569135(PQKBManifestationID)12204051(PQKBTitleCode)TC0000569135(PQKBWorkID)10540848(PQKB)10893972(MiAaPQ)EBC3019696(Au-PeEL)EBL3019696(CaPaEBR)ebr10671261(OCoLC)758384475(EXLCZ)99255000000006030120090626d2009 uy 0engur|n|---|||||txtccrGreen movement in business[electronic resource] /Karin E. Sanchez, editorNew York Nova Science Publishers20091 online resource (172 p.)NovinkaDescription based upon print version of record.1-60692-188-6 Includes bibliographical references and index.Novinka (Series)Industrial managementEnvironmental aspectsUnited StatesBusiness enterprisesEnvironmental aspectsUnited StatesGreen movementUnited StatesIndustrial managementEnvironmental aspectsBusiness enterprisesEnvironmental aspectsGreen movement658.4/083Sanchez Karin E1554360MiAaPQMiAaPQMiAaPQBOOK9910781865103321Green movement in business3815561UNINA03659nam 2200445 c 450 991050841010332120250415184117.09789515169419(CKB)19375582600041(EXLCZ)991937558260004120211125d2020 uy 0engur|||||||||||rdacordamtrdactPersonalized medicine legal and ethical challengesedited by Juli Mansnérus, Raimo Lahti and Amanda BlickHelsinki Faculty of Law, University of Helsinki2020HelsinkiFaculty of Law, University of Helsinki20201 online ressourceillustrationsForum Iuris1456-842X9789515169402 Preface /Raimo Lahti --Introduction /Juli Mansnérus, Raimo Lahti and Amanda Blick --Regulatory schemes in innovative healthcare and biomedicine /Raimo Lahti --Building the regulatory framework for personalized medicine : case Finland /Sandra Liede --'Precision medicine' : critical reflections on Europe's latest healthcare paradigm /Céline E. Dujardin --Genomic testing and giving consent on behalf of a child /Merike Helander --Germline gene therapy : safeguarding the best interests of the child /Amanda Blick --Over ten years since the adoption of the EU regulation on advanced therapy medical products – lessons learned thus far /Juli Mansnérus --On the lookout for experience : the legislative experiment of conditional pharmaceutical reimbursement in Finland /Waltter Roslin --Transatlantic comparative perspectives on patenting genome-editing technologies – a case study of patents on CRISPR/Cas9 technology /Liisa Vaaraniemi --Interpretation of the patient's need for help can be supported with machine learning /Lauri Lahti.The paradigm of personalized medicine is an emerging topic, triggering some specific legal and ethical challenges as regards data collection, sharing and use, informed consent, privacy and public trust, and the changing status of patients and social equality. These legislative developments and challenges have been discussed in light of the Finnish and the common-European experiences. During recent years, the Finnish legislative processes aiming at generating ‘innovation-friendly’ legislation for scientific research purposes as well as integrating genomic research results into the clinical setting have been heavily challenged by rapid developments in technology and medicine. In particular, there is a need to pursue the right balance between scientific and commercial interests, public health, and individual rights. We aim at providing insights into the legislative processes surrounding personalized medicine with a special focus on how the freedom of science, equitable access to healthcare, public health, and commercial issues that must be balanced with individual rights as expressed in the EU Charter and the Council of Europe’s Oviedo Convention on Human Rights and Biomedicine.Forum Iuris1456-842XBiomedical ResearchGene EditingLegislation, MedicalReimbursement MechanismsBiomedical Research.Gene Editing.Legislation, Medical.Reimbursement Mechanisms.Mansnérus Juli1984-edtLahti Raimo1946-edtBlick Amandaedt9910508410103321Personalized medicine2412512UNINAJönköping University